NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$46.40 +0.20 (+0.43 %)
(As of 05/24/2018 03:58 AM ET)
Previous Close$46.20
Today's Range$45.87 - $46.9450
52-Week Range$12.20 - $47.64
Volume454,269 shs
Average Volume1.14 million shs
Market Capitalization$2.28 billion
P/E Ratio-17.64
Dividend YieldN/A
Beta1.49

About Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn's disease. The company has collaboration agreements with Everest Medicines Limited; Axovant Sciences GmbH; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Debt-to-Equity Ratio0.10
Current Ratio15.28
Quick Ratio15.28

Price-To-Earnings

Trailing P/E Ratio-17.64
Forward P/E Ratio-16.87
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.34 million
Price / Sales107.04
Cash FlowN/A
Price / CashN/A
Book Value$11.86 per share
Price / Book3.91

Profitability

EPS (Most Recent Fiscal Year)($2.63)
Net Income$-91,400,000.00
Net Margins-321.04%
Return on Equity-34.08%
Return on Assets-23.82%

Miscellaneous

Employees159
Outstanding Shares49,230,000

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals's stock reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals (NASDAQ:ARNA) announced its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.80) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.68) by $0.12. The biopharmaceutical company earned $1.76 million during the quarter, compared to analysts' expectations of $4.02 million. Arena Pharmaceuticals had a negative return on equity of 34.08% and a negative net margin of 321.04%. The firm's revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.90) earnings per share. View Arena Pharmaceuticals' Earnings History.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Arena Pharmaceuticals.

What price target have analysts set for ARNA?

7 equities research analysts have issued 12-month target prices for Arena Pharmaceuticals' shares. Their forecasts range from $44.00 to $79.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $58.00 in the next year. View Analyst Ratings for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
  • 1. Needham & Company LLC analysts commented, "Arena mgmt provided a corporate update today in a 4Q17 conference call. Mgmt reiterated guidance for top-line results from etrasimod Phase 2 trial in Ulcerative Colitis (UC) later this month. Preclinical and Phase 1 data suggest the drug has the potential for differentiation in the S1P receptor modulator space. We await outcome, maintaining HOLD. Mgmt also discussed ralinepag Phase 3 trial design in Pulmonary Arterial Hypertension (PAH). Three trials are planned, two of which mgmt believes are independently sufficient for regulatory approval. Mgmt plans to provide more details around cost and time to completion mid-2018 after protocols are finalized." (3/14/2018)
  • 2. According to Zacks Investment Research, "Arena’s only approved product is Belviq, used for chronic weight management. Though it was the first obesity drug to be approved by the FDA in over a decade, is yet to impress with its performance. However, the company’s partnership agreements and efforts to improve the performance of the drug are impressive. We are also encouraged by the company’s cost-reduction initiatives to streamline the organization to support its development programs. Shares of the company have outperformed the industry in the last one year. On the flip side, Arena’s pipeline consists of early-to-mid stage candidates, still several years from commercialization. Plus, competition remains intense in the obesity market with both branded and generic players. " (3/9/2018)
  • 3. Cantor Fitzgerald analysts commented, "KOL event could fill in some important blank spaces. ARNA will host a lunch event on January 29 (12:30-1:30 pm) in NYC with two physician consultants to discuss modulators of S1P receptors and etrasimod, specifically. We believe the event could be helpful for investors as it relates to understanding important pharmacokinetic and pharmacodynamic properties of the drug candidate that we highlighted in a recent research report (here)." (1/17/2018)

Who are some of Arena Pharmaceuticals' key competitors?

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:
  • Mr. Amit D. Munshi, Chief Exec. Officer, Pres and Director (Age 50)
  • Mr. Kevin R. Lind, Chief Financial Officer and Exec. VP (Age 42)
  • Mr. Steven W. Spector J.D., Exec. VP, Gen. Counsel and Sec. (Age 53)
  • Mr. Vincent E. Aurentz, Chief Bus. Officer and Exec. VP (Age 50)
  • Ms. Cate Scanlon, VP of Global HR

Has Arena Pharmaceuticals been receiving favorable news coverage?

Media headlines about ARNA stock have been trending positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 0.33 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.06 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (10.92%), BlackRock Inc. (8.45%), Northern Trust Corp (1.10%), Rock Springs Capital Management LP (0.76%), Point72 Asset Management L.P. (0.69%) and Schwab Charles Investment Management Inc. (0.44%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christine Anna White and Steven W Spector. View Institutional Ownership Trends for Arena Pharmaceuticals.

Which major investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, A.R.T. Advisors LLC, X Square Capital LLC, Teacher Retirement System of Texas, GSA Capital Partners LLP, The Manufacturers Life Insurance Company and Legal & General Group Plc. View Insider Buying and Selling for Arena Pharmaceuticals.

Which major investors are buying Arena Pharmaceuticals stock?

ARNA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Rock Springs Capital Management LP, Senzar Asset Management LLC, DAFNA Capital Management LLC, Prosight Management LP, Allianz Asset Management GmbH and Allianz Asset Management GmbH. View Insider Buying and Selling for Arena Pharmaceuticals.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $46.40.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $2.28 billion and generates $21.34 million in revenue each year. The biopharmaceutical company earns $-91,400,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Arena Pharmaceuticals employs 159 workers across the globe.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]


MarketBeat Community Rating for Arena Pharmaceuticals (ARNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  506
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arena Pharmaceuticals (NASDAQ:ARNA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Arena Pharmaceuticals in the last 12 months. Their average twelve-month price target is $58.00, suggesting that the stock has a possible upside of 25.00%. The high price target for ARNA is $79.00 and the low price target for ARNA is $44.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.882.71
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $58.00$58.00$46.2857$38.8333
Price Target Upside: 25.00% upside45.91% upside13.45% upside54.78% upside

Arena Pharmaceuticals (NASDAQ:ARNA) Consensus Price Target History

Price Target History for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ:ARNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2018CitigroupReiterated RatingPositive ➝ Buy$62.00HighView Rating Details
3/20/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$63.00 ➝ $79.00HighView Rating Details
3/20/2018Wells Fargo & CoLower Price TargetPositive ➝ Outperform$53.00 ➝ $60.00HighView Rating Details
3/20/2018Needham & Company LLCUpgradeHold ➝ Buy$30.89 ➝ $60.00HighView Rating Details
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$44.00LowView Rating Details
1/17/2018Leerink SwannReiterated RatingOutperform ➝ Positive$53.00 ➝ $56.00LowView Rating Details
1/17/2018Cantor FitzgeraldReiterated RatingBuy$45.00LowView Rating Details
3/16/2017FBR & CoReiterated RatingOutperform$60.00MediumView Rating Details
8/10/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
8/8/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
(Data available from 5/24/2016 forward)

Earnings

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings History and Estimates Chart

Earnings by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings Estimates

2018 EPS Consensus Estimate: ($3.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.78)($0.78)($0.78)
Q2 20181($0.71)($0.71)($0.71)
Q3 20181($0.75)($0.75)($0.75)
Q4 20181($0.82)($0.82)($0.82)

Arena Pharmaceuticals (NASDAQ ARNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018($0.65)N/AView Earnings Details
5/8/2018Q1 2018($0.68)($0.80)$4.02 million$1.76 millionViewN/AView Earnings Details
3/14/2018Q4 2017($0.65)($0.35)$5.75 million$15.40 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.66)($0.65)$5.48 million$7.95 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.74)($0.77)$5.58 million$6.49 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.82)($0.90)$4.84 million$6.60 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.80)$1.60$14.12 million$85.40 millionViewN/AView Earnings Details
11/7/2016Q316($0.70)($0.50)$13.99 million$19.20 millionViewN/AView Earnings Details
8/8/2016Q216($1.00)($1.10)$10.44 million$9.50 millionViewN/AView Earnings Details
5/9/2016Q116($1.00)($0.90)$9.02 million$9.80 millionViewN/AView Earnings Details
2/29/2016Q415($1.30)($1.30)$8.26 million$7.80 millionViewN/AView Earnings Details
11/10/2015Q315($1.30)($1.10)$8.87 million$9.10 millionViewN/AView Earnings Details
8/5/2015Q215($1.40)($1.10)$10.95 million$9.18 millionViewN/AView Earnings Details
5/11/2015Q115($1.40)($1.00)$10.56 million$12.30 millionViewN/AView Earnings Details
3/2/2015Q414($1.20)($1.50)$10.36 million$9.20 millionViewN/AView Earnings Details
11/3/2014Q314($1.30)($0.50)$10.90 million$8.20 millionViewN/AView Earnings Details
8/1/2014Q2 14($1.10)($1.20)$9.81 million$12.80 millionViewN/AView Earnings Details
5/12/2014Q114($1.00)($1.20)$7.98 million$6.80 millionViewN/AView Earnings Details
2/27/2014Q413$0.20($1.10)$7.00 million$6.50 millionViewN/AView Earnings Details
11/7/2013Q313($1.20)($0.80)$5.30 million$3.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013$1.50$1.80$57.30 million$68.90 millionViewN/AView Earnings Details
4/30/2013Q1 2013$1.10$0.90$50.36 million$2.37 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.30)($1.00)$21.94 million$1.94 millionViewN/AView Earnings Details
11/6/2012Q312($1.10)($0.70)$3.72 million$1.50 millionViewN/AView Earnings Details
8/9/2012($0.80)($1.20)ViewN/AView Earnings Details
5/1/2012Q1 2012($1.30)($1.54)ViewN/AView Earnings Details
3/14/2012Q4 2011($1.50)($1.62)ViewN/AView Earnings Details
11/9/2011($1.40)($1.60)ViewN/AView Earnings Details
8/9/2011($1.50)($1.60)ViewN/AView Earnings Details
5/10/2011($2.10)($3.50)ViewN/AView Earnings Details
3/11/2011($2.20)($2.30)ViewN/AView Earnings Details
11/9/2010Q3 2010($2.30)($3.09)ViewN/AView Earnings Details
8/3/2010Q2 2010($2.80)($2.76)ViewN/AView Earnings Details
5/7/2010Q1 2010($3.20)($3.30)ViewN/AView Earnings Details
3/12/2010Q4 2009($3.00)($3.76)ViewN/AView Earnings Details
11/9/2009Q3 2009($3.40)($3.83)ViewN/AView Earnings Details
8/3/2009Q2 2009($4.80)($4.80)ViewN/AView Earnings Details
5/11/2009Q1 2009($6.90)($6.82)ViewN/AView Earnings Details
3/12/2009Q4 2008($7.80)($8.44)ViewN/AView Earnings Details
10/30/2008Q3 2008($8.30)($7.60)ViewN/AView Earnings Details
8/5/2008Q2 2008($7.30)($8.92)ViewN/AView Earnings Details
5/7/2008Q1 2008($6.70)($7.47)ViewN/AView Earnings Details
2/27/2008Q4 2007($8.20)($5.98)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Arena Pharmaceuticals (NASDAQ:ARNA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.88%
Institutional Ownership Percentage: 77.52%
Insider Trading History for Arena Pharmaceuticals (NASDAQ:ARNA)
Institutional Ownership by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Steven W SpectorEVPSell30,001$34.57$1,037,134.5734,691View SEC Filing  
5/12/2017Amit MunshiInsiderBuy25,000$1.19$29,750.0076,875View SEC Filing  
4/26/2017Amit MunshiInsiderBuy50,000$1.41$70,500.001,875View SEC Filing  
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.7285,529View SEC Filing  
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.0068,728View SEC Filing  
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.0082,876View SEC Filing  
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.0018,728View SEC Filing  
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.2568,728View SEC Filing  
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.0035,000View SEC Filing  
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00101,794View SEC Filing  
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00583,704View SEC Filing  
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00483,000View SEC Filing  
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arena Pharmaceuticals (NASDAQ ARNA) News Headlines

Source:
DateHeadline
Arena Pharmaceuticals (ARNA) Expected to Post Earnings of -$0.62 Per ShareArena Pharmaceuticals (ARNA) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - May 23 at 5:12 PM
Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the ...Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the ...
www.prnewswire.com - May 22 at 4:09 PM
Arena Pharmaceuticals (ARNA) CEO Presents at UBS Global Healthcare Brokers Conference (Transcript)Arena Pharmaceuticals' (ARNA) CEO Presents at UBS Global Healthcare Brokers Conference (Transcript)
seekingalpha.com - May 22 at 4:09 PM
Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International ConferenceArena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference
finance.yahoo.com - May 21 at 9:53 AM
Arena Pharmaceuticals (ARNA) Upgraded by BidaskClub to "Buy"Arena Pharmaceuticals (ARNA) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - May 18 at 5:13 PM
Arena Pharmaceuticals (ARNA) CEO Amit Munshi presents at Bank of America Merrill Lynch Healthcare Brokers Conference (Transcript)Arena Pharmaceuticals' (ARNA) CEO Amit Munshi presents at Bank of America Merrill Lynch Healthcare Brokers Conference (Transcript)
seekingalpha.com - May 18 at 11:13 AM
Small Caps Are the Place to Be for NowSmall Caps Are the Place to Be for Now
finance.yahoo.com - May 17 at 4:01 PM
Arena Pharmaceuticals (ARNA) CEO Amit Munshi on Q1 2018 Results - Earnings Call TranscriptArena Pharmaceuticals' (ARNA) CEO Amit Munshi on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 15 at 10:33 AM
Arena Pharmaceuticals, Inc. (ARNA) Given Average Recommendation of "Buy" by BrokeragesArena Pharmaceuticals, Inc. (ARNA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 13 at 10:13 AM
Having Some Good Luck With Biotech NamesHaving Some Good Luck With Biotech Names
finance.yahoo.com - May 11 at 4:17 PM
Analysts Offer Predictions for Arena Pharmaceuticals, Inc.s Q2 2018 Earnings (ARNA)Analysts Offer Predictions for Arena Pharmaceuticals, Inc.'s Q2 2018 Earnings (ARNA)
www.americanbankingnews.com - May 11 at 9:30 AM
Markets Make an Art of UnpredictabilityMarkets Make an Art of Unpredictability
finance.yahoo.com - May 9 at 4:09 PM
Arena Pharmaceuticals (ARNA) Releases Quarterly  Earnings Results, Misses Expectations By $0.12 EPSArena Pharmaceuticals (ARNA) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS
www.americanbankingnews.com - May 9 at 3:35 PM
Arena Pharmaceuticals misses by $0.10, misses on revenueArena Pharmaceuticals misses by $0.10, misses on revenue
seekingalpha.com - May 9 at 9:56 AM
Arena Reports Q1 Earnings: Loss Of $32 Million, Critical Etrasimod UpdateArena Reports Q1 Earnings: Loss Of $32 Million, Critical Etrasimod Update
seekingalpha.com - May 9 at 9:56 AM
Arena Pharmaceuticals (ARNA) Q1 Loss Wider Than ExpectedArena Pharmaceuticals (ARNA) Q1 Loss Wider Than Expected
www.zacks.com - May 9 at 9:56 AM
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial ResultsArena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 9:56 AM
$1.01 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter$1.01 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter
www.americanbankingnews.com - May 8 at 3:54 AM
 Brokerages Expect Arena Pharmaceuticals, Inc. (ARNA) Will Post Earnings of -$0.70 Per Share Brokerages Expect Arena Pharmaceuticals, Inc. (ARNA) Will Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - May 6 at 8:11 AM
Arena Pharmaceuticals (ARNA) Upgraded to Buy at ValuEngineArena Pharmaceuticals (ARNA) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - May 4 at 12:21 AM
BRIEF-Arena Pharma And Outpost Medicine Enter Into Licensing Agreement For Undisclosed Novel CompoundBRIEF-Arena Pharma And Outpost Medicine Enter Into Licensing Agreement For Undisclosed Novel Compound
www.reuters.com - May 2 at 4:07 PM
Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday ...Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday ...
www.prnewswire.com - May 2 at 4:07 PM
Arena Pharma (ARNA), Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel CompoundArena Pharma (ARNA), Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound
www.streetinsider.com - May 2 at 9:51 AM
Arena Investors Need To Pay Attention To Celgene And OzanimodArena Investors Need To Pay Attention To Celgene And Ozanimod
seekingalpha.com - May 2 at 9:51 AM
Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8Arena Pharmaceuticals to Release First Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, May 8
finance.yahoo.com - May 2 at 9:51 AM
Arena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel CompoundArena Pharmaceuticals and Outpost Medicine Enter into Licensing Agreement for Undisclosed Novel Compound
finance.yahoo.com - May 1 at 9:51 AM
Arena Pharmaceuticals (ARNA) to Release Earnings on MondayArena Pharmaceuticals (ARNA) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 9:39 AM
Walgreens Is A Buy - Cramers Lightning Round (4/26/18)Walgreens Is A Buy - Cramer's Lightning Round (4/26/18)
seekingalpha.com - April 29 at 3:58 PM
Pending Orexigen Sale Should Serve As A Warning SignPending Orexigen Sale Should Serve As A Warning Sign
seekingalpha.com - April 26 at 4:01 PM
Arena Pharmaceuticals (ARNA) Receives New Coverage from Analysts at CitigroupArena Pharmaceuticals (ARNA) Receives New Coverage from Analysts at Citigroup
www.americanbankingnews.com - April 20 at 3:01 PM
Arena Pharmaceuticals (ARNA) Rating Increased to Hold at BidaskClubArena Pharmaceuticals (ARNA) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 20 at 11:55 AM
Arena Pharmaceuticals (ARNA) Stock Rating Upgraded by Zacks Investment ResearchArena Pharmaceuticals (ARNA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 20 at 7:46 AM
Q2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical TrialsQ2 2018 Biotech Catalyst Watchlist: Phase 2 Clinical Trials
seekingalpha.com - April 19 at 4:13 PM
 Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Announce -$0.70 EPS Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Announce -$0.70 EPS
www.americanbankingnews.com - April 19 at 9:07 AM
Arena Pharmaceuticals, Inc. (ARNA) EVP Sells $1,037,134.57 in StockArena Pharmaceuticals, Inc. (ARNA) EVP Sells $1,037,134.57 in Stock
www.americanbankingnews.com - April 18 at 7:13 PM
Arena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from BrokeragesArena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 18 at 9:07 AM
Arena CEO: We have two great assets and are trying to bui...Arena CEO: We have two great assets and are trying to bui...
finance.yahoo.com - April 17 at 4:13 PM
Arena Pharmaceuticals (ARNA) Stock Rating Lowered by ValuEngineArena Pharmaceuticals (ARNA) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 17 at 11:05 AM
Arena Pharmaceuticals (ARNA) Rating Lowered to Sell at BidaskClubArena Pharmaceuticals (ARNA) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 16 at 9:16 PM
Arena Pharmaceuticals, Inc. (ARNA) Sees Significant Increase in Short InterestArena Pharmaceuticals, Inc. (ARNA) Sees Significant Increase in Short Interest
www.americanbankingnews.com - April 14 at 1:40 AM
Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue?Arena Pharmaceuticals (ARNA) Up 7% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 13 at 4:08 PM
Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual MeetingArena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting
finance.yahoo.com - April 12 at 10:54 AM
This $3 Medical Device Stock be Worth $9-14 with Impending Product LaunchThis $3 Medical Device Stock be Worth $9-14 with Impending Product Launch
finance.yahoo.com - April 5 at 8:24 AM
 Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Announce Quarterly Sales of $1.01 Million Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Announce Quarterly Sales of $1.01 Million
www.americanbankingnews.com - April 4 at 4:18 AM
Arena Pharmaceuticals, Inc. (ARNA) Expected to Post Earnings of -$0.70 Per ShareArena Pharmaceuticals, Inc. (ARNA) Expected to Post Earnings of -$0.70 Per Share
www.americanbankingnews.com - April 2 at 7:22 AM
Arena Pharmaceuticals (ARNA) Upgraded to "Outperform" by Wells FargoArena Pharmaceuticals (ARNA) Upgraded to "Outperform" by Wells Fargo
www.americanbankingnews.com - March 31 at 12:12 AM
Arena Pharmaceuticals Inc (NASDAQ:ARNA): Earnings Growth Remains ElusiveArena Pharmaceuticals Inc (NASDAQ:ARNA): Earnings Growth Remains Elusive
finance.yahoo.com - March 29 at 4:01 PM
Arena Pharmaceuticals (ARNA) Stock Rating Lowered by Zacks Investment ResearchArena Pharmaceuticals (ARNA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:45 PM
BidaskClub Lowers Arena Pharmaceuticals (ARNA) to BuyBidaskClub Lowers Arena Pharmaceuticals (ARNA) to Buy
www.americanbankingnews.com - March 28 at 11:56 AM
Arena Pharmaceuticals (ARNA) Earns "Buy" Rating from Cantor FitzgeraldArena Pharmaceuticals (ARNA) Earns "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - March 27 at 10:23 PM

SEC Filings

Arena Pharmaceuticals (NASDAQ:ARNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arena Pharmaceuticals (NASDAQ:ARNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arena Pharmaceuticals (NASDAQ ARNA) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.